Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or influenza across Europe. 

Clinical Outcomes, Mortality Risk Factor of RSV, Influenza in Hospitalized Adults

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Many women remain unaware that the Affordable Care Act (ACA) mandates cost-free preventive services; however, ongoing legal challenges threaten the future of this coverage.

 Women’s Awareness of ACA Preventive Services Remains Low Amid Ongoing Legal Challenges

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.

FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML

Viet Le, PA-C, Intermountain Health, gives insights into the benefits cardio-renal-metabolic care models provide for patients in need. 

Fostering Interdisciplinary Communication: How Cardio-Renal-Metabolic Care Models Optimize Care Delivery 

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone - Participating Faculty

ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease

Medical Costs for Managing Chronic Kidney Disease and Related Complications in Patients With Chronic Kidney Disease and Type 2 Diabetes

FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

eAppendix: ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease

eAppendix: FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone

Supplements and Featured Publications

Publications

Chronic Kidney Disease

Compendium